Ojjaara
These highlights do not include all the information needed to use OJJAARA safely and effectively. See full prescribing information for OJJAARA. OJJAARA (momelotinib) tablets, for oral useInitial U.S. Approval: 2023
4a672fd1-eb7b-4aa9-9b23-845e4b5dc400
HUMAN PRESCRIPTION DRUG LABEL
Sep 15, 2023
GlaxoSmithKline LLC
DUNS: 167380711
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Momelotinib
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (13)
Momelotinib
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (13)
Momelotinib
Product Details
FDA regulatory identification and product classification information